Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


High Cost Of Research Leads MNCs To Shanghai-Based WuXi Pharmatech (China)

This article was originally published in PharmAsia News

Executive Summary

Thanks to moves by multinational pharmaceutical companies, Shanghai-based WuXi Pharmatech is expected to have more chemists on its staff than the world's largest drug maker, Pfizer. Pfizer and other MNCs look to WuXi for research that could lead to a possible blockbuster drug for them as they face a need to reduce costs, in part by trimming personnel levels. That has allowed WuXi to flourish to the extent it was able to transform itself into a public company whose market value has doubled in four months. CEO Ge Li acknowledges the company exists because of excessive research costs elsewhere. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts